Prophylactic efficacy of aerosolized liposomal (AmBisome) and non-lipsomal (Fungizone) amphotericin B in murine pulmonary aspergillosis
The DOI matches its Crossref record.
Abstract
Pulmonary aspergillosis is a serious opportunistic disease in patients with immune suppression. Prophylactic measures would be highly beneficial because treatment often fails after infection occurs. The principle objective of this study was to evaluate the prophylactic efficacy of aerosolized liposomal (AmBisome) and non-liposomal (Fungizone) amphotericin B in a murine model. Immunocompromised mice were treated prophylactically for 3 days with AmBisome or Fungizone using a small particle aerosol generator. Intranasal challenge was with a high (10(8)), medium (10(7)), or low (10(6)) level of Aspergillus fumigatus spores. AmBisome nebulized more uniformly, resulting in very consistent chamber air concentrations. Total dose, however, was nearly the same for each formulation. Survival was prolonged in animals treated with both formulations at the 10(8) and 10(7) challenge levels. Quantitative lung cultures showed that organisms were completely cleared from the lungs in the low challenged group, with both formulations, whereas the high challenge proved overwhelming for both formulations. With the middle challenge, however, AmBisome cleared 80% of the lungs, whereas Fungizone cleared none. Lung drug retention of AmBisome treated animals was more than eight times higher than Fungizone at the time of challenge. BUN and creatinine values in animals treated with both formulations were not elevated. These results suggest that AmBisome is more effective than Fungizone when given as a prophylactic aerosol in this model.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Aspergillus Infections in Transplant Recipients
Singh, N., & Paterson, D. L. (2005) · Clinical Microbiology Reviews · doi:10.1128/cmr.18.1.44-69.2005 · Cited by 579
Carrier effects on biological activity of amphotericin B
Brajtburg, J., & Bolard, J. (1996) · Clinical Microbiology Reviews · doi:10.1128/cmr.9.4.512 · Cited by 310
Heijerman, H., Westerman, E., Conway, S., & Touw, D. (2009) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2009.04.005 · Cited by 264
Therapeutic Liposomal Dry Powder Inhalation Aerosols for Targeted Lung Delivery
Willis, L., Hayes, D., & Mansour, H. M. (2012) · Lung · doi:10.1007/s00408-011-9360-x · Cited by 148
“It shows fewer side effects than administration of liposome-free AmB, has been reported as effective in animal models of pulmonary aspergillosis, is well tolerated in immunocompromised patients, and liposomal formulation shows increased pulmonary deposition and retention [61–65].”
BackgroundAerosolized nanostructured itraconazole as prophylaxis against invasive pulmonary aspergillosis
Alvarez, C. A., Wiederhold, N. P., McConville, J. T., Peters, J. I., Najvar, L. K., Graybill, J. R., Coalson, J. J., Talbert, R. L., Burgess, D. S., Bocanegra, R., et al. (2007) · Journal of Infection · doi:10.1016/j.jinf.2007.01.014 · Cited by 43
Metadata
- Authors
- Allen, S. D., Sorensen, K. N., Neial, M. J., Durrant, C., & Proffit, R. T.
- Venue
- Journal of Antimicrobial Chemotherapy
- Publisher
- Oxford University Press (OUP)
- Published
- 1994
- Volume
- 34
- Issue
- 6
- Pages
- 1001-1013
- ISSN
- 0305-7453 (ISSN-L)
- 1460-2091
- OpenAlex
- W1970880244
- Cited by
- 105
- References
- 0
- FWCI
- 3.75
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prophylactic efficacy of aerosolized liposomal (AmBisome) and non-lipsomal (Fungizone) amphotericin B in murine pulmonary aspergillosis. https://app.cochat.ai/papers/10.1093/jac/34.6.1001
- The paper
- Allen, S. D., Sorensen, K. N., Neial, M. J., Durrant, C., & Proffit, R. T. (1994). Prophylactic efficacy of aerosolized liposomal (AmBisome) and non-lipsomal (Fungizone) amphotericin B in murine pulmonary aspergillosis. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/34.6.1001
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.